Clinical Trials Browser

Interventional × vandetanib × Clear all

NCT01298323 2026-04-17

Study to Determine if Contacting Patients With MTC More Frequently Results in Earlier Detection and Treatment of Signs and Symptoms of AEs and Thus a Decrease in the Percentage of Time Patients Experience AEs During First 12 Months on Vandetanib Treatment

Phase 3 Completed

205 enrolled 10 charts

Neoplasm Metastasis, Carcinoma, Medullary

NCT04211337 2026-03-19

LIBRETTO-531

Phase 3 Active not recruiting

291 enrolled 16 charts 1 FDA

Carcinoma, Medullary

NCT01582191 2025-10-27

Vandetanib and Everolimus in Treating Patients With Advanced or Metastatic Cancer

Phase 1 Completed

Neoplasm Metastasis, Neoplasms, Recurrence

NCT01496313 2025-10-03

To Compare The Effects Of Two Doses Of Vandetanib In Patients With Advanced Medullary Thyroid Cancer

Phase 4 Completed

81 enrolled 15 charts

Neoplasm Metastasis, Thyroid Neoplasms, Carcinoma, Medullary

NCT00410761 2025-09-24

An Efficacy Study Comparing ZD6474 to Placebo in Medullary Thyroid Cancer

Phase 3 Completed

331 enrolled 15 charts

EndocrineHead & Neck

Familial medullary thyroid carcinoma, Thyroid Neoplasms, Carcinoma, Medullary

NCT01601808 2025-03-13

ViP

Phase 2 Completed

Gastrointestinal

Pancreatic Neoplasms

NCT02299999 2025-01-15

SAFIR02_Breast

Phase 2 Active not recruiting

Breast Neoplasms

NCT00418886 2024-12-31

ZEAL

Phase 3 Completed

698 enrolled 16 charts

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06482086 2024-12-05

Efficacy of Organoid-Based Drug Screening to Guide Treatment for Locally Advanced Thyroid Cancer

Phase 2 Recruiting

Locally Advanced Thyroid Gland Carcinoma

NCT01876784 2024-07-23

VERIFY

Phase 3 Completed

238 enrolled 12 charts

EndocrineHead & Neck

Differentiated Thyroid Cancer

NCT00537095 2024-04-19

Efficacy and Safety of Vandetanib (ZD6474) in Patients With Metastatic Papillary or Follicular Thyroid Cancer

Phase 2 Completed

164 enrolled 10 charts

Thyroid Neoplasms

NCT02117167 2024-01-10

SAFIR02_Lung

Phase 2 Completed

Non-small Cell Lung Cancer Metastatic

NCT04760288 2024-01-05

AcceleRET-MTC

Phase 3 Withdrawn

Carcinoma, Medullary

NCT01934335 2021-11-01

Effect of Vandetanib on Cellular Markers in Invasive Breast Cancer

Phase 2 Terminated

12 enrolled 10 charts

Breast Neoplasms

NCT01586624 2021-10-07

A Phase I Trial of Vandetanib (AZD6474) and Selumetinib (AZD6244) for Solid Tumours Including Non Small Cell Lung Cancer (VanSel-1)

Phase 1 Completed

61 enrolled 23 charts

Carcinoma, Non-Small-Cell Lung, Neoplasms

NCT03630120 2021-07-14

Adaptive Tyrosine Kinase Inhibitor (TKI) Therapy In Patients With Thyroid Cancer

Phase 2 Terminated

6 enrolled 9 charts

EndocrineHead & Neck

Thyroid cancer, medullary, Thyroid Cancer, Papillary, Thyroid Diseases, Thyroid Neoplasms, Adenocarcinoma, Follicular, Carcinoma, Medullary

NCT02495103 2021-01-26

Vandetanib in Combination With Metformin in People With HLRCC or SDH-Associated Kidney Cancer or Sporadic Papillary Renal Cell Carcinoma

Phase 1/2 Terminated

7 enrolled 10 charts

Carcinoma, Renal Cell

NCT01183559 2021-01-22

A Trial of ZD6474, Paclitaxel, Carboplatin, 5-Fluorouracil, and Radiation Therapy Followed by Surgery

Phase 1 Completed

9 enrolled 10 charts

Gastrointestinal

Esophageal Neoplasms, Stomach Neoplasms

NCT01414426 2021-01-14

Vandetanib in Preventing Head and Neck Cancer in Patients With Precancerous Head and Neck Lesions

Phase 2 Completed

20 enrolled 7 charts

Head & NeckOther neoplasm

Lymphoid Interstitial Pneumonia, Squamous Cell Carcinoma of Head and Neck, Precancerous Conditions

NCT00514046 2020-12-22

Vandetanib to Treat Children and Adolescents With Medullary Thyroid Cancer

Phase 1/2 Completed

17 enrolled 25 charts

Multiple Endocrine Neoplasia, Carcinoma, Medullary, Multiple Endocrine Neoplasia Type 2a, Multiple Endocrine Neoplasia Type 2b

NCT01823068 2020-12-07

Vandetanib in Advanced NSCLC With RET Rearrangement

Phase 2 Completed

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT02239952 2020-10-08

HGG-TCP (High Grade Glioma - Tumor Concentrations of Protein Kinase Inhibitors)

Phase NA Unknown

Glioma, Neoplasms

NCT02015065 2020-03-30

Phase II Trial of Vandetanib in Children and Adults With Wild-Type Gastrointestinal Stromal Tumors

Phase 2 Completed

9 enrolled 14 charts

GIST

NCT02638428 2020-03-19

Genomics-Based Target Therapy for Children With Relapsed or Refractory Malignancy

Phase 2 Unknown

Other solid neoplasm

Relapsed Pediatric Solid Tumor

NCT00613626 2020-02-11

Cisplatin + Etoposide +/- Concurrent ZD6474 in Previously Untreated Extensive Stage Small Cell Lung Cancer

Phase 2 Completed

74 enrolled 19 charts

Small Cell Lung Carcinoma

NCT00272350 2019-12-05

ZD6474 to Treat Advanced Brain Cancer in Patients

Phase 1 Completed

Brain Neoplasms, Glioma, Neoplasms, Disease Progression

NCT01191892 2019-05-16

Carboplatin and Gemcitabine Hydrochloride With or Without Vandetanib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Urinary Tract Cancer

Phase 2 Completed

Urinary Bladder Neoplasms, Ureteral Neoplasms, Urethral Neoplasms

NCT00459121 2019-03-26

Vandetanib, Carboplatin, and Paclitaxel in Treating Patients With Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer That Can Be Removed by Surgery

Phase 2 Terminated

2 enrolled 4 charts

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT02142036 2019-03-13

MetAction

Phase 2 Completed

Neoplasm Metastasis

NCT00441142 2019-03-05

Zactima

Phase 1/2 Completed

119 enrolled 15 charts

Glioblastoma, Gliosarcoma

NCT00923247 2018-11-29

A Targeted Phase I/II Trial of ZD6474 (Vandetanib; ZACTIMA) Plus the Proteasome Inhibitor, Bortezomib (Velcade ), in Adults With Solid Tumors With a Focus on Hereditary or Sporadic, Locally Advanced or Metastatic Medullary Thyroid Cancer (MTC)

Phase 1/2 Terminated

22 enrolled 21 charts

Neoplasms, Thyroid Neoplasms, Carcinoma, Medullary

NCT00745732 2018-11-14

Radiation Therapy (XRT) and ZD6474 in Non-Small Cell Lung Cancer (NSCLC)

Phase 1 Terminated

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT00566995 2018-10-30

Phase II Study of Vandetanib in Individuals With Kidney Cancer

Phase 2 Completed

37 enrolled 16 charts

Carcinoma, Renal Cell, Kidney Neoplasms

NCT00880334 2018-09-18

Randomized Study of Docetaxel +/- Vandetanib in Metastatic TCC

Phase 2 Completed

149 enrolled 12 charts

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT00687297 2018-05-30

Study of Vandetanib Combined With Chemotherapy to Treat Advanced Non-small Cell Lung Cancer

Phase 2 Completed

162 enrolled 9 charts

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT00098345 2018-05-07

Efficacy and Tolerability of ZD6474 in Patients With Thyroid Cancer

Phase 2 Completed

40 enrolled 12 charts

Thyroid Neoplasms

NCT00364351 2018-01-25

Efficacy Trial Comparing ZD6474 With Erlotinib in NSCLC After Failure of at Least One Prior Chemotherapy

Phase 3 Completed

1,574 enrolled 13 charts

Carcinoma, Non-Small-Cell Lung

NCT00500292 2018-01-25

A Phase II Study of 2 Doses of ZD6474 (Vandetanib) in Combination With FOLFOX vs FOLFOX Alone for the Treatment of Colorectal Cancer

Phase 2 Completed

109 enrolled 8 charts

Neoplasms

NCT01539655 2017-05-02

Vandetanib

Phase 1 Completed

Carcinoma, Medullary

NCT00937417 2017-04-24

S0716 Vandetanib and Docetaxel in Treating Patients With Advanced Solid Tumors

Phase 1 Withdrawn

BreastCNSEndocrineGenitourinaryHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Thyroid Cancer, Papillary, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Lung Neoplasms, Prostatic Neoplasms, Salivary Gland Neoplasms, Thyroid Neoplasms, Adenocarcinoma, Follicular, Carcinoma, Medullary, Esthesioneuroblastoma, Olfactory, Breast Neoplasms, Male, Thyroid Carcinoma, Anaplastic

NCT00481845 2017-02-07

Phase 2 Anastrozole and Vandetanib (ZD6474) in Neoadjuvant Treatment of Postmenopausal Hormone Receptor-Positive Breast Cancer

Phase 2 Terminated

1 enrolled 8 charts

Breast Neoplasms

NCT00358956 2017-01-30

A Study To Assess ZD6474 (ZACTIMA™) Monotherapy In Locally Advanced or Metastatic Hereditary Medullary Thyroid Cancer

Phase 2 Completed

19 enrolled 10 charts

EndocrineHead & Neck

Familial medullary thyroid carcinoma, Thyroid Neoplasms, Carcinoma, Medullary

NCT00686036 2016-12-21

ZENITH

Phase 2 Terminated

17 enrolled 4 charts

Prostatic Neoplasms

NCT00872989 2016-12-19

S0904: Docetaxel With or Without Vandetanib in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Phase 2 Completed

129 enrolled 17 charts

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT00659438 2016-12-05

Efficacy and Safety of Zactima™ in Patients With Castration-refractory Metastatic Prostate Cancer

Phase 2 Completed

95 enrolled 12 charts

Prostatic Neoplasms

NCT00752986 2016-12-05

ZACFAST

Phase 2 Terminated

39 enrolled 7 charts

Breast Neoplasms, Neoplasm Metastasis

NCT01661179 2016-12-05

Evaluate the Safety and Tolerability of Vandetanib in Japanese Patients With Medullary Thyroid Carcinoma

Phase 1/2 Completed

14 enrolled 7 charts

Neoplasm Metastasis, Carcinoma, Medullary

NCT00753714 2016-10-17

ZELIG

Phase 2 Completed

124 enrolled 11 charts

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Pleural Effusion

NCT00508001 2016-10-10

Phase II Study of Best Support Care (BSC) Plus ZD6474(Vandetanib) in Patients With Inoperable Hepatocellular Carcinoma (HCC)

Phase 2 Completed

67 enrolled 12 charts

Gastrointestinal

Carcinoma, Hepatocellular, Neoplasms

NCT00597116 2016-10-10

An Efficacy and Safety Study With Vandetanib to Treat Inoperable or Relapsed Malignant Mesothelioma

Phase 2 Terminated

25 enrolled 8 charts

Other solid neoplasmThoracic

Mesothelioma, Recurrence